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Abstract
Background: Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are clinically distinct neurodevelopmental 
genetic disorders that map to 15q11-q13. The primary phenotypes are attributable to loss of expression of imprinted 
genes within this region which can arise by means of a number of mechanisms. The most sensitive single approach to 
diagnosing both PWS and AS is to study methylation patterns within 15q11-q13; however many techniques exist for 
this purpose. Given the diversity of techniques available, there is a need for consensus testing and reporting guidelines.
Methods: Testing and reporting guidelines have been drawn up and agreed in accordance with the procedures of the 
UK Clinical Molecular Genetics Society and the European Molecular Genetics Quality Network.
Results: A practical set of molecular genetic testing and reporting guidelines has been developed for these two 
disorders. In addition, advice is given on appropriate reporting policies, including advice on test sensitivity and 
recurrence risks. In considering test sensitivity, the possibility of differential diagnoses is discussed.
Conclusion: An agreed set of practice guidelines has been developed for the diagnostic molecular genetic testing of 
PWS and AS.
Clinical Background
Prader-Willi syndrome (PWS, OMIM ref. 176270) is
characterised by severe hypotonia and feeding difficulties
in early infancy, followed in later infancy or early child-
hood by excessive eating and gradual development of
morbid obesity (unless eating is controlled by dietary
restriction or behaviour modification). Motor milestones
and language development are delayed. All individuals
have some degree of cognitive impairment, although
some will have an IQ within the normal range. A distinc-
tive behavioral phenotype (with temper tantrums, stub-
bornness, manipulative behavior, and obsessive-
compulsive characteristics) is common. Hypogonadism is
present in both males and females, and manifests as geni-
tal hypoplasia, incomplete pubertal development, and in
most, infertility. Short stature is common; characteristic
facial features, strabismus, and scoliosis are often present,
and non-insulin-dependent diabetes mellitus often
occurs in obese individuals. Consensus diagnostic clinical
criteria for PWS have been developed [1,2]; however con-
firmation of diagnosis requires genetic testing.
Angelman syndrome (AS, OMIM ref. 105830) is char-
acterised by severe developmental delay, absent or
severely limited speech, gait ataxia and/or tremulousness
o f  t h e  l i m b s ,  a n d  a  u n i q u e  b e h a v i o r  w i t h  a  h a p p y
demeanor that includes frequent and sometimes inappro-
priate laughter, smiling, and excitability. In addition,
microcephaly and seizures are common. Affected indi-
viduals usually have a characteristic electroencephalogra-
phy (EEG) appearance with striking high voltage activity.
Developmental delay is first noted at around six months
of age; however, the unique clinical features of AS may
not manifest until after one year of age, and it can take
several years before the correct clinical diagnosis is obvi-
ous. The diagnosis of AS rests upon a combination of
clinical features as well as molecular genetic testing and/
or cytogenetic analysis. Consensus clinical diagnostic cri-
teria for AS have been developed [3,4]. * Correspondence: simon.ramsden@cmft.nhs.uk
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Genetic Background
The proximal long arm of human chromosome 15
(15q11-q13) contains a cluster of imprinted genes, which
are under the control of a bipartite imprinting centre [5].
Some of these genes are expressed from the paternal or
maternal chromosome only. PWS arises from the loss of
function of paternally expressed 15q11-q13 genes as a
result of either a paternally derived de novo deletion of
this region, maternal uniparental disomy (UPD) of chro-
mosome 15 or the silencing of the paternal alleles by an
imprinting defect on the paternal chromosome. So far,
several genes preferentially or exclusively expressed from
the paternal chromosome have been described: MKRN3,
MAGEL2, NDN, PWRN1, C15orf2, SNURF-SNRPN and
several C/D box small nucleolar RNA (snoRNA) genes
(see figure 1). At least two of these genes SNRPN and
NDN, have differentially methylated CpG islands in their
promoter regions that are methylated on the maternal
chromosome leading to silencing of the maternal allele.
Whereas most of the snoRNA genes are present as single
genes (SNORD64, SNORD107, SNORD108, SNORD109A
and  SNORD109B), the two snoRNA genes SNORD116
and SNORD115  are present in 24 and 47 gene copies,
respectively. It has been recently demonstrated that defi-
ciency of SNORD116  (previously  HBII-85) snoRNAs
causes the key characteristics of the PWS phenotype
[6,7], however one or more additional genes in the region
are likely to contribute.
In AS the major disease mechanism is either a de novo
maternally derived deletion of 15q11-q13, paternal UPD
or an imprinting defect affecting the maternal chromo-
some. In addition point mutations in the E6-AP ubiq-
uitin-protein ligase gene (UBE3A) are known to cause AS
[8,9], Imprinted UBE3A expression is restricted to brain
cells where expression is exclusively from the maternal
chromosome and disruption of expression of this gene is
now considered to be the major cause of the disease.
There is one further gene in 15q11-q13 that is preferen-
tially expressed from the maternal chromosome in brain
and fibroblasts; ATP10C [10]. This gene is not expressed
in AS patients with a deletion, uniparental disomy or an
imprinting defect; however, its role in the disease is
unclear. In contrast to PWS, approximately 10% of
patients suspected of having AS have a genetic defect of
unknown aetiology and alternative diagnoses are consid-
ered below.
Microdeletions in a small number of patients with PWS
or AS have helped define an imprinting centre (IC),
which has two critical regions, the AS-SRO (shortest
region of deletion overlap) and the PWS-SRO [5]. By
analysing a very large series of PWS and AS patients with
an imprinting defect it has been shown that the vast
majority of imprinting defects are primary epimutations
that have occurred spontaneously in the absence of DNA
sequence changes [11]. Furthermore, in approximately
one third of patients with AS and a primary epimutation,
the imprinting defect is present in a subset of cells only
(somatic mosaicism), indicating that it occurred after fer-
tilisation [12]. A summary of the causative genetic mech-
anisms and recurrence risks underlying these two
diseases is given in tables 1 and 2.
Figure 1 Genes within the PWS and AS critical region. Blue boxes represent paternally expressed genes; blue vertical lines, snoRNAs; red boxes, 
maternally expressed genes; black boxes, biallelically expressed genes and arrow heads represent the orientation of transcription. IC, imprinting cen-
tre; BP, common breakpoint cluster region.Ramsden et al. BMC Medical Genetics 2010, 11:70
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There are a number of cytogenetic and molecular
approaches to the confirmation of these two disorders.
The most common is DNA-based methylation testing to
detect abnormal parent-specific methylation within the
PWS and AS critical region. This will detect more than
99% of individuals with PWS and approximately 80% of
individuals with AS. UBE3A  sequence analysis detects
mutations in approximately a further 10% of individuals
with AS, however UBE3A analysis is not considered fur-
ther in this article.
Methods
Current practice in the molecular analysis and reporting
of PWS and AS was assessed by consideration of the
external quality assessment returns submitted to the
European Molecular Genetics Quality Network (EMQN)
and the United Kingdom External Quality Assessment
Scheme (UKNEQAS) over a five year period. The guide-
lines in this article were posted on the web-site of the UK
Clinical Molecular Genetics Society (CMGS) for consul-
tation and amendment between 19th May, 2008 and 6th
January, 2010 and heads of the constituent laboratories
were invited to comment. In the light of feedback amend-
ments were made and the final document was ratified by
the CMGS Executive Committee on 15th January, 2010. In
addition they were approved by the European Molecular
Genetics Quality Network (EMQN) Steering Group on
22nd January, 2010.
Results
Strategies for the analysis of PWS and AS
The approach to the laboratory diagnosis of AS and PWS
depends on many factors, including the availability of
samples, the arrangement of laboratory services and the
patterns of referral. The most sensitive single approach to
diagnosing PWS and AS is to study methylation patterns
within 15q11-q13 using molecular genetic techniques.
These will detect deletions, UPD and imprinting defects
by establishing either a solely maternal methylated
imprint (PWS) or paternal methylated imprint (AS).
Broadly speaking, methylation studies take one of two
forms:
(i) The detection of methylation status solely at the
SNRPN  locus by use of methylation specific PCR
(MS-PCR) or Southern blot analysis. This approach
will confirm a diagnosis but will provide no further
information regarding the disease mechanism neces-
sitating follow up studies (FISH and/or microsatellite
analysis).
(ii) The simultaneous assessment of methylation sta-
tus and genomic dosage at numerous sites across the
15q11-q13 region, by the use of methylation sensitive
Table 1: Molecular defects and recurrence risks in PWS.
Genetic defect Proportion of cases Recurrence risk
De novo deletion of 15q11-q13 on the 
paternal chromosome
75-80% <1%
Maternal uniparental disomy (UPD) of 
chromosome 15
20-25% <1%
Imprinting defects (with an imprinting 
centre deletion excluded)
≈1% <1%
Imprinting centre deletion ≈ 10-15% of patients with an imprinting 
defect
Up to 50% (if present in father)
Table 2: Molecular defects and recurrence risks in AS.
Genetic defect Proportion of cases Recurrence risk
De novo deletion of 15q11-q13 on the 
maternal chromosome
70-75% <1%
Paternal uniparental disomy (UPD) of 
chromosome 15
3-7% <1%
Imprinting defect (with an imprinting 
centre deletion excluded)
2-3% <1%
Deletions of the imprinting centre ≈ 10-15% of patients with an imprinting 
defect
Up to 50% (if present in mother)
UBE3A mutation ≈10% 50% if present in mother
No identifiable molecular abnormality ≈10% Unknown (up to 50%)Ramsden et al. BMC Medical Genetics 2010, 11:70
http://www.biomedcentral.com/1471-2350/11/70
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multiplex ligation-dependent probe amplification
(MS-MLPA). This approach will confirm the diagno-
sis and further identify the presence of a causative
deletion. However, in the absence of a deletion follow
up studies (microsatellite analysis) are required to dis-
tinguish between UPD and an imprinting defect.
It is essential to note that approach (i) will not distin-
guish between the two classes of imprinting defect (ie.
between one with no detectable deletion in the IC region
and one due to a microdeletion of the IC). MS-MLPA
however will give some limited information in this regard
(see below). It is reasonable to request a standard karyo-
type analysis on the proband at the same time as a molec-
ular analysis in order to investigate possible alternative
explanations for the clinical presentation (if the PWS/AS
investigations turn out to be negative). Upon the confir-
mation of a diagnosis, cytogenetic analysis of parental
samples is recommended to investigate the possibility of
balanced rearrangements, and genetic counseling should
be offered to the family if the referral is not from a spe-
cialist in clinical genetics. Figure 2 shows an example of
testing strategies for approaches (i) and (ii).
Molecular genetic testing methods
MS-PCR
This is based on sodium bisulphite treatment of DNA fol-
lowed by PCR using primers specific for differentially
methylated sites within the SNRPN  exon 1/promoter
regions. Two approaches have been shown to work reli-
ably in interlaboratory comparisons: Kubota et al [13]
describe the use of two primer pairs that can be used sep-
arately (simplex PCR) or in combination (duplex PCR).
However, it is strongly recommended that the primers are
not used in a simplex reaction as this has been shown to
result in spurious DNA amplification and/or misdiagno-
sis resulting from PCR failure [14]. Zeschnigk et al [15]
describe an alternative assay with one common primer
that anneals to both alleles and one specific primer each
for the methylated and the unmethylated allele. In this
case, the three primers are always used together in one
reaction. The SNRPN exon 1/promoter region is highly
conserved but contains a few very rare single nucleotide
polymorphisms (SNPs) within the primer binding sites
(see additional file 1). These changes have yet to be
reported on current open access databases [K. Buiting
personal communication].
Southern Blot Analysis
The 15q11-q13 methylation status can be assayed by
Southern blotting and a number of probes have been
used in this regard. It is now considered essential that
probes are chosen to assess methylation status at the
SNRPN  locus, rather than any other locus within the
15q11-q13 region. L48.25X, a 4.05 kb probe spanning
exon 1 of the SNRPN gene detects the methylation at a
CpG island within exon 1 of SNRPN. Genomic DNA
digested with XbaI and the methylation-sensitive enzyme
NotI shows 4.2 kb, 3.0 kb and 0.9 kb bands in unaffected
individuals. The 4.2 kb band represents the methylated
allele, which is absent in AS patients with a large deletion,
paternal UPD or an imprinting defect. The 3.0 kb and the
0.9 kb bands represent the unmethylated allele which is
absent in PWS patients with a large deletion, maternal
UPD or an imprinting defect [16-18]. Whilst L48.25X
requires pre-annealing, KB17 (a subclone of L48.25X)
provides a useful alternative. Hybridisation with KB17
gives a 4.2 kb maternal and a 0.9 kb paternal band on
XbaI and NotI digested DNA. It does not require pre-
annealing, but is only 600 bp so can be easily washed off
the filter in error. The final wash should be 2 x SSC at
65°C (for probe availability, please contact the authors). A
rare restriction fragment length polymorphism affecting
a NotI site in intron 1 can result in a 3.9 kb fragment for
the unmethylated allele and can lead to false positive
results in short run gels where the 4.05 and the 3.9 kb
bands are not resolved (see figure 3). Figure 2 Testing strategies for the molecular analysis of PWS and 
AS based upon (i) an initial methylation analysis at the SNRPN lo-
cus and (ii) an initial MLPA analysis.
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Alternative techniques
A small number of laboratories use alternative methods
of methylation analysis including PCR following restric-
tion digestion with a methylation sensitive enzyme [19],
melt-curve analysis [20] and pyrosequencing [21]. These
techniques have not been widely adopted but have all
been used successfully within a diagnostic context.
MS-MLPA
MS-MLPA provides a means to simultaneously detect
copy number changes and DNA methylation within
15q11-q13 in a semi-quantitative manner. Most laborato-
ries using this approach make use of a commercially
available MS-MLPA kit available from MRC Holland
http://www.mrc-holland.com. The ME028-B1 version of
this kit contains 46 probes, 32 of which are specific for
sequences in or close to the PWS/AS critical region on
15q11-q13. As a control for copy number changes, 14
probes outside the PWS/AS region are included. Among
the PWS/AS specific probes, seven probes are methyla-
tion-sensitive and contain a HhaI restriction site. Five of
the methylation sensitive probes from the PWS/AS
region represent differentially methylated sites (four for
the SNURF-SNRPN exon1/promoter region and intron 1
and one for the promoter region of NDN), one is from the
completely unmethylated promoter regions of UBE3A,
and another one is from the completely methylated
SNORD116 snoRNA gene cluster region. The kit contains
two additional methylation sensitive control probes for
completely unmethylated sequences from other chromo-
somes that will indicate complete digestion by the HhaI
enzyme.
Dosage analysis by MS-MLPA offers the opportunity to
detect large deletions, the most frequent molecular
lesions in patients with PWS and AS. In rare cases, a
larger deletion can extend telemetric and include the
probe for APBA2. Another advantage of the ME028-B1
MLPA kit is that small deletions affecting the UBE3A
gene or the SNORD116 gene region can be detected.
MS-MLPA has become the method of choice in many
diagnostic laboratories as it investigates methylation sta-
tus at several loci, thereby reducing the risk of a false pos-
itive or false negative result due to SNPs; in addition, if
one probe fails there are four remaining probes with
which to assess methylation status.
MS-MLPA (ME028-B1) will also identify IC deletions
in PWS and AS cases with an imprinting defect. The kit
contains four probes for the SNRPN exon 1/promoter/
intron 1, a region which represents the smallest region of
deletion overlap in patients with PWS (PWS-SRO) and
an IC deletion. Furthermore, two probes for SNRPN exon
3 and 7 are also included, which are deleted in most cases
with an IC deletion. There are two probes which can be
used to detect IC deletions in patients with AS and an
imprinting defect. Both lie in the smallest region of dele-
tion overlap found in patients with AS and an imprinting
defect (AS-SRO).
There appears to be some naturally occurring variation
in dosage and methylation status which must be taken
into account when interpreting MS-MLPA results;
(i) For the two most centromeric probes, NIPA1 and
TUBGCP5, copy number variation has been observed
in healthy individuals. This has been attributed to
deletions and duplications encompassing these two
probes, and this complicates the definition of class 1
and class II deletions. This copy number variation has
been observed in healthy individuals and seems to be
non-pathogenic however it cannot be excluded as
contributing to the phenotype in some individuals.
Variation in the hybridization efficiency due to a copy
number variation is also observed for the SNRPN
exon u1B probe.
(ii) SNPs under hybridisation binding sites can influ-
ence probe signals. Consequently laboratories must
exercise extreme caution when interpreting results
from a single probe.
(iii) Normal variation in the degree of methylation at
the NDN locus is frequently observed.
For prenatal diagnosis it should be noted that chorionic
villi samples show a significant hypomethylation at the
Figure 3 The potential for mis-diagnosis as a result of a Not I re-
striction site polymorphism in SNRPN exon 1 (i) Genomic organi-
sation. (ii) Southern blot analysis using probe KB17 (lane 1 - PWS; lane 
2 - AS; lane 3 - Normal (with Not I polymorphism); lane 4 - Normal).
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NDN  locus and also for the SNRD116  probe (12273-
L13798), which in blood DNA is completely methylated
(Karin Buiting and Jasmin Beygo, personal communica-
tion). These results suggest that the methylation of the
NDN locus is not fully established in chorionic tissue. It is
therefore recommended that only the methylation status
of the SNRPN locus is considered in the context of prena-
tal diagnosis.
It should be noted that the current commercially avail-
able MS-MLPA kits are not certified for diagnostic use
and must be fully validated in individual laboratories
prior to implementation. We recommend that recurrent
variation observed in the MRC MS-MLPA kit is reported
to the manufacturer to facilitate future kit development.
Microsatellite Analysis
When a diagnosis of AS or PWS is confirmed with any of
the above techniques microsatellite analysis will often be
required to distinguish between the various disease
mechanisms. There are many microsatellites suitable for
this purpose [22-27], and it is outside the scope of this
article to provide a comprehensive list of suitable mark-
ers. However, it is worth noting the following markers
that have been used widely in the past and are known to
be compromised.
• D15S113 (LS6-1/2). This is a CA repeat from within
the critical region. The presence of null alleles (or
non-amplification alleles) have been observed with
this marker and can complicate the analysis of AS and
PWS cases. Under certain conditions, a non-amplifi-
cation allele can be misinterpreted as a small deletion.
The frequency of these alleles in families without AS
has been estimated to be around 4%. Alternative
primers can be designed; however, this marker is best
avoided.
•  D15S817. The presence of three alleles has been
observed with this marker with certain primer sets
due to complex duplications in the region where the
marker is located. Since there is a low frequency/den-
sity of useful markers for the more centromeric PWS/
AS region, the use of the following primer pair
(D15S817F, 5'-TGGAACCAATAGGATAGACAC-3'
D15S817R, 5'-GGTCAGCCTCCATAATCA-3') can
resolve this problem.
Once the diagnosis of PWS or AS has been confirmed
using methylation analysis, the interpretation of the mic-
rosatellite results is as follows:
a) Uniparental inheritance inside the critical region, 
biparental outside In this case the disease is due to a
deletion of the critical region. In rare cases, microsatel-
lites may be used to confirm a smaller deletion within the
critical region, however, laboratories must not interpret
results from a single informative microsatellite without
supporting evidence.
b) Uniparental inheritance both inside and outside the 
critical region In this case, the disease is due to unipa-
rental disomy. It is important to note that AS and PWS
can be caused by either chromosomal isodisomy or het-
erodisomy. Further, heterodisomy or isodisomy at a single
locus does not necessarily reflect the disomy status along
the entire chromosome depending on the rate and level of
crossing over and the meiotic stage at which non-segre-
gation occurred.
c) Biparental inheritance both inside and outside the 
critical region In this case the disease is presumed to be
due to an imprinting defect.
Interpretation of diagnostic testing results
Normal Methylation Result
A normal methylation pattern rules out PWS on the basis
of most known cases to date and around 70-75% of AS
cases. Despite early reports of possible deletion mosa-
icism in PWS [28,29] the case for deletion mosaicism
remains unproven [30]. However in the case of the rare
AS patients with a sporadic imprinting defect approxi-
mately one third appear mosaic for DNA methylation
[11] and this group contains patients with an atypical
phenotype that can overlap with PWS [31]. It is therefore
essential that laboratories understand the limitations of a
normal methylation result in PWS. In the case of AS, if
the clinical suspicion remains high with normal methyla-
tion then it is recommended to undertake UBE3A analy-
sis as mutations in this gene will have a recurrence risk of
up to 50%, depending on the carrier status of the mother.
Deletions
The  de novo interstitial deletion of chromosome 15,
del(15)(q11-q13), which includes the entire imprinted
domain plus several non-imprinted genes extends
approximately 6 Mb and is found in the majority of
patients with PWS and AS. In both syndromes, the same
region is affected, but in PWS the deletion is always on
the paternal chromosome, whereas in AS it is always on
the maternal chromosome. The deletion occurs at a fre-
quency of about 1/15,000 newborns and is probably one
of the most common pathogenic deletions observed in
humans. In a few patients, the region is deleted as the
result of an unbalanced translocation. At the molecular
level, two classes of deletions (class I and II) can be distin-
guished. In both classes, the distal breakpoints are close
to, but telomeric to the P gene (breakpoint region 3, BP3,
see figure 1). In class I deletions (30-40% of deletion
cases), the proximal breakpoint is centromeric to the
marker D15S541 (breakpoint region 1, BP1). In class II
deletions (60-70% of deletion cases) the proximal break-
point is between D15S541 and D15S543 (breakpoint
region 2, BP2). The clustering of the deletion breakpoints
is due to the presence of large duplicated sequence
stretches of 200-400 kb in size in the common breakpointRamsden et al. BMC Medical Genetics 2010, 11:70
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regions that are susceptible to non-homologous cross-
overs [32,33]. Cases of de novo deletions should be fur-
ther investigated by cytogenetic analysis to rule out the
presence of (very rare) cytogenetic rearrangements in the
appropriate parent (father for PWS and mother for AS)
that may predispose to a deletion.
UPD
The second most frequent finding in PWS is maternal
UPD (upd(15)mat) of chromosome 15. These patients
have two maternal copies of chromosome 15 and lack a
paternal copy. As the PWS genes are silent on the mater-
nal chromosome, upd(15)mat is associated with a com-
plete loss of function of these genes. The reciprocal
finding is made in some patients with AS. These patients
have two paternal copies of chromosome 15 and lack a
maternal copy (upd(15)pat). In brain cells UBE3A is silent
on the paternal chromosome, so upd(15)pat is associated
with a complete loss of function of this gene in this tissue.
Uniparental disomy arises in most cases of PWS as a
result of a combination of meiotic and mitotic errors in
female meiosis. During meoisis, the diploid set of chro-
mosomes (n = 46) is reduced to a haploid set (n = 23).
Nondisjunction of the homologous chromosomes 15 dur-
ing female meiosis I or nondisjunction of the two sister
chromatids during female meiosis II results in an oocyte
with two chromosomes 15 or no chromosome 15. In
these cases, fertilisation by a sperm with one chromo-
some 15 will result in a zygote which is trisomic or mono-
somic for chromosome 15 respectively. These conditions
are not compatible with normal development, but can be
'rescued' by loss of one chromosome 15 from a trisomic
cell or duplication of the paternal chromosome 15 in a
monosomic cell. With trisomy rescue, in two-thirds of
cases, one of the two maternal chromosomes will be lost
from the trisomic cell, resulting in a normal set of chro-
mosomes. If, however, the paternal chromosome is lost,
the cell is left with two maternal chromosomes 15
(upd(15)mat). Duplication of the paternal chromosome
15 in a monosomic cell will lead to upd(15)pat.
Alternative mechanisms for UPD such as complemen-
tation involving both a nullisomic and disomic gamete or
rescued paternal 15 trisomy have also been reported,
however are considered rare [34].
Imprinting Defects
There are a small number of patients with either PWS
(1%) or AS (2-4%) that show biparental inheritance for
chromosome 15 markers, both inside and outside the
critical region, but have an abnormal methylation pat-
tern, characteristic for the syndrome. These patients are
presumed to have an imprinting defect.
The majority of patients with an imprinting defect are
sporadic cases without any detectable mutations in the IC
region at the DNA sequence level. However in 10-15% of
cases, the imprinting defect is caused by a microdeletion
of the imprinting centre (IC). In most cases, the IC dele-
tion is a familial mutation associated with a 50% recur-
rence risk, however in some cases the IC deletion is de
novo  or a consequence of germ line mosaicism in the
father or the mother. In these families, the recurrence risk
ranges from 0-50%, depending on the degree of the mosa-
icism in the germ line [11]. An IC deletion is the only kind
of mutation found in patients with an imprinting defect
with the exception of a single case where a familial inver-
sion has been identified which disrupts the IC region
[35].
Few laboratories are equipped to fully analyse these
rare cases; however, it is important they are referred on to
a specialist laboratory in order to confirm the nature of
the imprinting defect and better understand the recur-
rence risk.
Reporting
It is recommended that laboratories do not use joint
PWS/AS report templates. It is essential to state clearly
on the report the method(s) used to carry out genetic
analysis, with an appropriate reference; for example,
"Zeschnigk  et al. 1997  Eur J Hum Genet,  5:94-99", or
"ME028 MRC Holland http://www.mrc-holland.com)". It
is essential that, where relevant, reports should inform as
to the likelihood of recurrence, and, if the referral origi-
nates from a non-genetics specialist, genetic counselling
is offered to all families where a diagnosis of AS or PWS
is confirmed. In these cases cytogenetic analysis of the
proband and father (for PWS) or mother (for AS) must be
considered to rule out the remote possibility of cytoge-
netic rearrangements. More specific recommendations
are as follows:
Diagnostic referral for PWS (using either MS-PCR or 
Southern analysis)
(i) NORMAL RESULT. Normal methylation result. This
result excludes paternal deletion, uniparental disomy and
an imprinting defect. The result makes a diagnosis of PWS
highly unlikely. The sensitivity of the test should be stated
on the report.
(ii) DIAGNOSIS CONFIRMED: Absence of paternal
allele at 15q11-q13 by methylation analysis. This result
confirms the diagnosis of PWS. There is a common usage
of terms such as "normal" and "abnormal" methylation
pattern of the maternal or paternal allele/chromosome,
however it is not appropriate to use these terms when the
etiology is unknown. It is only appropriate to describe the
imprinting pattern as "Abnormal" in patients with
imprinting defect where it has been demonstrated that
the paternal chromosome is aberrantly methylated. In
deletion cases one allele is not present and therefore is
not abnormally methylated. The same is true for maternal
UPD, where the paternal allele is missing. With MS-PCRRamsden et al. BMC Medical Genetics 2010, 11:70
http://www.biomedcentral.com/1471-2350/11/70
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a n d  S o u t h e r n  a n a l y s i s  i t  i s  b e s t  t o  d e s c r i b e  w h a t  i s
observed; that is absence or presence of the relevant
parental band and not simply to state that a methylation
pattern typical of PWS is present. The laboratory should
state that these approaches cannot determine the molec-
ular cause of the result; and should request that parental
blood samples be collected for microsatellite analysis in
order to determine the mutational mechanism and recur-
rence risk.
Diagnostic referral for PWS (MS-MLPA method)
(i) NORMAL RESULT: Normal methylation and normal
dosage at 15q11-q13. This result excludes paternal dele-
tion, uniparental disomy and imprinting defect. A diagno-
sis of PWS is highly unlikely. The sensitivity of the test
should be mentioned on the report.
(ii) DIAGNOSIS CONFIRMED - DELETION IDENTI-
FIED: Absence of paternal allele at 15q11-q13. This result
confirms a diagnosis of PWS. The molecular cause of PWS
is due to 15q11-q13 deletion.
(iii) DIAGNOSIS CONFIRMED - NO DELETION
IDENTIFIED: Absence of a paternal allele at 15q11-q13
by MLPA, normal dosage at 15q11-q13. This result con-
firms the diagnosis of PWS. The molecular cause of PWS
may be due to maternal UPD or an imprinting defect.
Laboratories should recommend microsatellite studies on
the family to help confirm or exclude UPD.
(iv) DIAGNOSIS CONFIRMED - DELETION OF THE
IMPRINTING CENTRE IDENTIFIED: Absence of pater-
nal allele for SNRPN exon 1/intron 1 probes and possibly
SNRPN u1B probe. IC. deletion detected. This result con-
firms the diagnosis of PWS. IC deletions are associated
with a recurrence risk of up to 50%. In case of an IC dele-
tion the father should be investigated for the presence of
the deletion since familial IC deletion may have conse-
quences for other family members.
Diagnostic referral for AS (using either MS-PCR or Southern 
analysis)
(i) NORMAL RESULT: Normal methylation. This result
excludes maternal deletion, uniparental disomy and
imprinting defects. The diagnosis of AS can not be con-
firmed in this patient. This result does not exclude a diag-
nosis of AS. See also the comments regarding reporting
"abnormal mathylation patterns" in PWS (above). It may
be appropriate to offer UBE3A analysis after a clinical re-
assessment of the patient.
(ii) DIAGNOSIS CONFIRMED: Absence of maternal
allele at 15q11-q13 by methylation analysis. This result
confirms the diagnosis of AS. This may be due to a de novo
deletion, uniparental disomy or an imprinting defect. Col-
lection of blood samples from the proband and parents is
essential to determine the molecular cause and recur-
rence risk.
Diagnostic referral for AS (MS-MLPA method)
(i) NORMAL RESULT: Normal methylation and, normal
dosage at 15q11-q13. This result excludes maternal dele-
tion, uniparental disomy and imprinting defect. This
result does not exclude a diagnosis of AS. It may be appro-
priate to offer UBE3A analysis after a clinical re-assess-
ment of the patient.
(ii) DIAGNOSIS CONFIRMED - DELETION IDENTI-
FIED: Absence of maternal allele at 15q11-q13 by methy-
lation analysis. This result confirms a diagnosis of AS. The
molecular cause of AS is due to 15q11-q13 deletion.
(iii) DIAGNOSIS CONFIRMED - NO DELETION
IDENTIFIED: Absence of maternal allele at 15q11-q13 by
methylation analysis. This result confirms the diagnosis of
AS. The molecular cause of AS may be due to paternal
UPD or an imprinting defect. Recommend microsatellite
analysis to confirm/exclude UPD.
Prenatal diagnosis
When the diagnosis has been confirmed and the molecu-
lar cause has been established in the index case, prenatal
diagnosis can be performed. For cases of de novo dele-
tions or disomy the recurrence risk is very low, however
prenatal testing can be offered for reassurance. For cases
of familial imprinting mutations due to an inherited dele-
tion of the imprinting centre prenatal diagnosis should be
offered as the recurrence risk is high (50%). Methylation
status at SNRPN exon 1 is established early in embryonic
development and testing DNA extracted from both amni-
otic cells and chorionic villi has been shown to give reli-
able results [36]. Fluorescent in-situ hybridisation (FISH)
and/or microsatellite analysis can be used where appro-
priate to support the methylation results.
For cases of imprinting mutations due to deletions of
the imprinting centre that are either de novo or a conse-
quence of germ line mosaicism in the parent, the recur-
rence risk is difficult to predict but may be as high as 50%.
In cases of imprinting defects with no detectable muta-
tion, the recurrence risk appears to be low, however since
the possibility of recurrence cannot be excluded a prena-
tal diagnosis should be offered. For these latter two sce-
narios prenatal diagnosis is performed by methylation
analysis only.
Differential diagnoses
Prader-Willi Syndrome
Diagnoses which need to be considered in infants with
hypotonia include congenital myopathies, the congenital
form of myotonic dystrophy and type 1 spinal muscular
atrophy. Peroxisomal disorders should also be ruled out if
chromosome 15 methylation is normal [37]. A further
phenotype which presents with neonatal hypotonia and
later onset obesity is attributable to deletions or epimuta-Ramsden et al. BMC Medical Genetics 2010, 11:70
http://www.biomedcentral.com/1471-2350/11/70
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tions of the DLK1/GTL2  locus on 14q32 as well as
upd(14)mat [38,39].
When considering the differential diagnosis of older
children with learning disability and obesity, Cohen syn-
drome, Borjesson-Forssman-Lehman syndrome (males),
Bardet-Biedl syndrome and Alstrom syndrome along
with chromosomal disorders including, diploid/triploid
mosaicism and 1p36 microdeletion syndrome, should be
considered [40].
Angelman Syndrome
A r o u n d  1 0 %  o f  p a t i e n t s  w i t h  a  c l i n i c a l  d i a g n o s i s  o f
Angelman syndrome have no demonstrable abnormality
at 15q11-q13 using the techniques described here. In rare
cases, these patients may be mosaic for an imprinting
defect. However, it is more likely that there is an alterna-
tive clinical diagnosis and a careful review of the patient's
h i s t o r y ,  c l i n i c a l  f e a t u r e s  a n d  E E G  f i n d i n g s  i s  r e c o m -
mended. One diagnosis which should be considered in
girls is Rett syndrome (male Rett syndrome is rare but
possible). It is extremely difficult to distinguish between
Rett syndrome and AS during infancy when both can
present with acquired microcephaly, ataxia and frequent
smiling. Later, Rett syndrome may be distinguished by
the presence of a history of developmental regression, the
emergence of stereotypic hand-wringing movements,
bouts of hyperventilation and the presence of vasomotor
disturbance. If there is a very early onset of seizures,
within the first few months, mutations within the CDKL5
gene should be considered [41]. Mowat-Wilson syn-
drome, caused by mutations in the ZFHX1B  gene on
chromosome 2, is associated with severe learning disabil-
ity, limited speech, seizures and characteristic facial fea-
tures that resemble those of AS. In addition Hirschsprung
disease, congenital cardiac defects and agenesis of the
c o r p u s  c a l l o s u m  m a y  b e  a s s o c i a t e d  w i t h  m u t a t i o n s  i n
ZFHX1B. A strong indication is the characteristic appear-
ance of the ear lobes which are upturned and look like
"shell pasta". Pitt-Hopkins Syndrome (PHS) is a sporadic
condition caused by mutations or deletions of the TCF4
gene on chromosome 18q; patients present with absent
speech, seizures and facial features resembling AS,
together with a sociable personality. The facial appear-
ance in PHS coarsens with age and the lips in particular
become prominent. Episodes of hyperventilation and
apnoea may develop [42]. Recently, Zweier et al. reported
several patients with autosomal recessive PHS caused by
deletions or point mutations in the NRXN1 and CTNAP2
genes. Breathing anomalies, epilepsy and autistic features
were prominent features in these cases [43]. An X-linked
Angelman-like condition caused by mutations in the
SLC9A6 gene has been reported [44]. Specific character-
istics to look for in this condition are a slim body habitus
and an unusually fast EEG rhythm. Several chromosome
abnormalities have phenotypes that overlap with AS. The
most common are the 1p36 subtelomeric deletion, a
microdeletion of 17q21, and a terminal deletion of 22q13.
Xq28 duplication including the MECP2  gene may also
present with a phenotype suggestive of AS in males [45].
Profound neonatal hypotonia, the presence of constipa-
tion and Rett-like features distinguish Xq28 duplication
from AS patients [46]. Recently several patients with
2q23.1 microdeletions encompassing the methyl binding
domain gene MBD5 and a clinical and behavioural phe-
notype reminiscent of Angelman syndrome were
reported [47]. Seizures, ataxia and sleep disturbance were
common findings in this group of patients. Microarray
studies are therefore clearly indicated in patients with
AS-like features. Finally, some rare metabolic disorders
may present with AS-like symptoms. Methyltetrahydro-
folate reductase (MTHFR) deficiency and adenylosucci-
nate lyase deficiency have been reported as presenting
with learning disbility, ataxia, seizures, autistic features
and excessive laughter [48,49]. With MTHFR deficiency
homocystinuria is present and treatment with folic acid
and betaine may alleviate, though not completely cure
symptoms.
Discussion/conclusion
A practical set of molecular genetic testing guidelines has
been developed for PWS and AS. In addition advice is
given on appropriate reporting policies including advice
on test sensitivity and recurrence risks. Feedback has
been obtained from participants of the 2007 PWS/AS
EMQN external quality assessment scheme (49 laborato-
ries from 20 countries) and the heads of the constituent
laboratories of the CMGS (46 laboratories from the UK).
All comments received were minor; largely typographic
corrections and some points of clarity. There was no dis-
agreement on the recommendations made. All comments
have been incorporated into this final document.
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